About the Authors
- Justyna A. Dobrowolska
-
Affiliation Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America
- Tom Kasten
-
Affiliation Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America
- Yafei Huang
-
Affiliation Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America
- Tammie L. S. Benzinger
-
Affiliation Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, United States of America
- Wendy Sigurdson
-
Affiliations Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, United States of America
- Vitaliy Ovod
-
Affiliation Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America
- John C. Morris
-
Affiliations Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, United States of America
- Randall J. Bateman
-
* E-mail: batemanr@wustl.edu
Affiliations Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, United States of America, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, United States of America
Competing Interests
The authors have read the journal's policy and have the following potential or perceived conflicts: Eli Lilly provided antibodies for this study. Neither RJB, nor his family, owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical company. He receives research support from the Alzheimer's Association, an anonymous foundation, and Merck research collaboration, and is funded by NIH grants # R01NS065667, U17AG032438, U01AG042791, and P50AG005681. RJB is currently Director of the Dominantly Inherited Alzheimer's Network (DIAN) Trials Unit which has underway an antidementia drug clinical trial in collaboration with Eli Lilly and Roche. RJB heads the DIAN Pharma Consortium (AIP, Biogen Idec, Elan, Eisai, EnVivo, Genentech, Eli Lilly, Novartis, Pfizer, Roche, Sanofi-Aventis). He receives research support from both the DIAN Pharma Consortium and from Eli Lilly and Roche for the current clinical trial. In 2007, RJB co-founded the biotechnology company C2N Diagnostics and serves as one of its scientific advisors. In the past, RJB has participated in a clinical trial of an antidementia drug sponsored by Eli Lilly and has served as a consultant for the following companies: Pfizer, DZNE, Probiodrug AG, Medscape, En Vivo (SAB). He has also been an invited speaker at: Bristol-Myers Squibb, Eli Lilly, Merck, Pfizer, Elan, Wyeth, Novartis, Abbott, Biogen Idec, Roche and Takeda Foundation. RJB is co-inventor on U.S. patent 7,892,845: “Methods for measuring the metabolism of neurally derived biomolecules in vivo,” Washington University, with RJB and JAD as co-inventors, has also submitted the U.S. non-provisional patent application “Methods for measuring the metabolism of CNS derived biomolecules in vivo,” serial #12/267,974. RJB is also co-inventor on U.S. Provisional Application 61/728,692: “Methods of Diagnosing Amyloid Pathologies Using Analysis of Amyloid-Beta Enrichment Kinetics.” Neither JCM, nor his family, owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. JCM has participated or is currently participating in clinical trials of antidementia drugs sponsored by the following companies: Janssen Immunotherapy and Pfizer. JCM has served as a consultant for Lilly USA. He receives research support from Eli Lilly/Avid Radiopharmaceuticals and is funded by NIH grants # P50AG005681, P01AG003991, P01AG026276 and U19AG032438. TLSB served on an advisory board for Eli Lilly in 2011; and, for projects unrelated to the study presented herein, has research funding from Avid Radiopharmaceuticals. The remaining co-authors (TK, YH, VO, and WS) have declared that no competing interests exist. Please note that the potential or perceived conflicts disclosed in the Competing Interests section do not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: JAD RJB. Performed the experiments: JAD TK TLSB WS RJB. Analyzed the data: JAD TK YH RJB. Contributed reagents/materials/analysis tools: YH VO WS JCM TLSB RJB. Wrote the paper: JAD TK RJB.